In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined with tumour-specific genetic alterations, hypoxia is a dominant factor in the angiogenic phenotype. Cellular adaptation to hypoxia is an important requirement of tumour progression independent of angiogenesis. The adaptive changes, insofar as they alter hypoxia-induced apoptosis, are likely to determine responsiveness to antiangiogenic strategies. To investigate this adaptation of tumour cells to hypoxia, we recreated in vitro the in vivo situation of chronic intermittent exposure to low-oxygen levels. The colon carcinoma cell lines HT29 and HCT116 were subjected to 40 episodes of sublethal hypoxia (4 h) three times a week. The resulting two hypoxia-conditioned cell lines have been maintained in culture for more than 2 years. In both cell lines changes in doubling times occurred: in HT29 an increase, and in HCT116 a decrease. Cell survival in response to hypoxia and to DNA damage differed strikingly in the two cell lines. The HT29 hypoxia-conditioned cells were more resistant than the parental line to a 24 h hypoxic challenge, while those from HCT116 surprisingly were more sensitive. Sensitivity to cisplatin in vitro was also significantly different for the hypoxia-conditioned compared with the parental lines, suggesting a change in pathways leading to apoptosis following DNA damage signaling. The growth of both conditioned cell lines in vivo as xenografts in immunodeficient (SCID) mice was more rapid than their parental lines, and was accompanied in each by evidence of enhanced vascular proliferation as a consequence of the hypoxia-conditioning. Thus the changes in apoptotic susceptibility were independent of altered angiogenesis. The derivation of these lines provides a model for events within hypoxic regions of colon cancers, and for the acquisition of resistance and sensitivity characteristics that may have therapeutic implications for the use of antiangiogenesis drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with previous observations that the activation of HIF activity through its overexpression (28) or chronic hypoxia (52) leads to increased tumor growth.”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108 · cited 1×
“Interactions with the cell matrix have been demonstrated to determine the behavior of in vivo models of human cancer, and efforts to target these interactions clinically have been made (Melchiori et al, 1992; Coussens et al, 2002; Egeblad and Werb, 2002).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
(1989) · PubMed · Cited by 3,343
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 7×
“Western analysis showed similar profiles of HIF-1a protein expression (data not shown).”
BackgroundInfluentialHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 2×
“…event is responsible for both increased susceptibility to apoptosis and the altered doubling time, consistent with the previous demonstration that the hypoxic environment facilitates mutational events (Graeber et al, 1996) and plausible especially in a cell line deficient in DNA mismatch repair.”
BackgroundISCN 1995 An international system for human cytogenetic nomenclature
Mitelman, F. (1995) · Cited by 1,930
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,926
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00101-6 · Cited by 1,068
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 2×
“A similar procedure was followed to derive hypoxia-conditioned cells from HCT116/p53 / , a p53-knockout cell line that has been well characterized in previous studies (Bunz et al, 1999).”
MethodResultp53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Self-citationBrown, J. M. (1999) · PubMed · Cited by 699
Moulder, J. E., & Rockwell, S. (1984) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(84)90301-8 · Cited by 606
Hamilton, T. C., Winker, M. A., Louie, K. G., Batist, G., Behrens, B. C., Tsuruo, T., Grotzinger, K. R., McKoy, W. M., Young, R. C., & Ozols, R. F. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90551-9 · Cited by 535
Definitive evidence for hypoxic cells influencing cure in cancer therapy.
Bush, R. S., Jenkin, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H. A., Dembo, A. J., & Pringle, J. F. (1978) · PubMed · Cited by 454
Mutator phenotypes in human colorectal carcinoma cell lines.
Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J., & Meuth, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6319 · Cited by 424
Direct coupling of the cell cycle and cell death machinery by E2F
Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., & Lowe, S. W. (2002) · Nature Cell Biology · doi:10.1038/ncb868 · Cited by 421
Shimizu, S., Eguchi, Y., Kamiike, W., Itoh, Y., Hasegawa, J., Yamabe, K., Otsuki, Y., Matsuda, H., & Tsujimoto, Y. (1996) · PubMed · Cited by 361
Role of collagenases in tumor cell invasion
Liotta, L. A., Thorgeirsson, U. P., & Garbisa, S. (1982) · Cancer and Metastasis Review · doi:10.1007/bf00124213 · Cited by 336
The hypoxic tumor cell: A target for selective cancer chemotherapy
Kennedy, K. A., Teicher, B. A., Rockwell, S., & Sartorelli, A. C. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90235-x · Cited by 287
104 candidate genes for the hypoxic tumor phenotype
Koong, A. C., Denko, N. O., Schindler, C., Le, Q. T., Terris, D. T., Ibrahim, H. Z., Goffinet, D. R., & Giaccia, A. J. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)90122-0 · Cited by 285
Rice, G. C., Hoy, C., & Schimke, R. T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5978 · Cited by 249
Yao, K. S., Xanthoudakis, S., Curran, T., & O'Dwyer, P. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.5997 · Cited by 243
Self-citationCandidate genes for the hypoxic tumor phenotype.
Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L. M., Koch, C., Evans, S. M., Ibrahim, H., Le, Q., Terris, D. J., et al. (2000) · PubMed · Cited by 239
Teicher, B. A., Holden, S. A., Al-Achi, A., & Herman, T. S. (1990) · PubMed · Cited by 225
Kartner, N., Shales, M., Riordan, J. R., & Ling, V. W. T. (1983) · PubMed · Cited by 199
Multidrug-resistance phenotype in Chinese hamster ovary cells.
Ling, V. W. T., Kartner, N., Sudo, T., Siminovitch, L., & Riordan, J. R. (1983) · PubMed · Cited by 194
Castro-Rivera, E., Ran, S., Thorpe, P., & Minna, J. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403969101 · Cited by 188
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., & Hamilton, T. C. (1997) · PubMed · Cited by 178
Al, W., & Kd, T. (1985) · PubMed · Cited by 166
Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines.
Buller, A. L., Clapper, M. L., & Tew, K. D. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10471-9 · Cited by 155
The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin ?
Leker, R. R., Aharonowiz, M., Greig, N. H., & Ovadia, H. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.030 · Cited by 152
Kim, C., Tsai, M. H., Osmanian, C., Graeber, T. G., Lee, J. E., Giffard, R. G., DiPaolo, J. A., Peehl, D. M., & Giaccia, A. J. (1997) · PubMed · Cited by 143
Pandey, P., Avraham, S., Kumar, S., Nakazawa, A., Place, A., Ghanem, L., Rana, A., Kumar, V., Majumder, P. K., Avraham, H., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10140 · Cited by 132
Going malignant: the hypoxia‐cancer connection in the prostate
Hochachka, P. W., Rupert, J. L., Goldenberg, L., Gleave, M., & Kozlowski, P. (2002) · BioEssays · doi:10.1002/bies.10131 · Cited by 117
Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions
Tannock, I. F., & Guttman, P. (1981) · British Journal of Cancer · doi:10.1038/bjc.1981.37 · Cited by 114
Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors
North, S., Moenner, M., & Bikfalvi, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.08.007 · Cited by 113
Zhang, L., & Hill, R. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3038 · Cited by 107
Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance
Sakata, K., Kwok, T. T., Murphy, B., Laderoute, K., Gordon, G., & Sutherland, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.405 · Cited by 104
Yao, K.-S., & O'Dwyer, P. J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00544-v · Cited by 94
Self-citationApoptosis in Human Adenocarcinoma HT29 Cells Induced by Exposure to Hypoxia
Yao, K.-S., Clayton, M., & O'Dwyer, P. J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.2.117 · Cited by 92
Self-citationTherapeutic Advantage of Hypoxic Cells in Tumors: A Theoretical Study
Brown, J. M., & Koong, A. C. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.3.178 · Cited by 91
Hypoxia Selection of Death-resistant Cells
Dong, Z., & Wang, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312225200 · Cited by 87
Melchiori, A., Albini, A., Ray, J., & Stetler‐Stevenson, W. G. (1992) · PubMed · Cited by 85
Stephan, S., Datta, K., Wang, E., Li, J., Brekken, R. A., Parangi, S., Thorpe, P. E., & Mukhopadhyay, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0808 · Cited by 82
O'Dwyer, P. J., Yao, K.-S., Ford, P., Godwin, A. K., & Clayton, M. (1994) · PubMed · Cited by 52
Self-citationÅmellem, Ø., Stokke, T., Sandvik, J. A., Smedshammer, L., & Pettersen, E. O. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3497 · Cited by 46
Garay, M., Gaarde, W. A., Monia, B. P., Nero, P., & Cioffi, C. L. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00412-8 · Cited by 41
Vasilevskaya, I. A., & O'Dwyer, P. J. (1999) · PubMed · Cited by 39
Self-citationHolmbeck, K., Bianco, P., & Birkedal‐Hansen, H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00196-x · Cited by 19
Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy.
Chaplin, D. J., & Hill, S. A. (2002) · PubMed · Cited by 8
Evaluation ofin vitro drug screening leads using experimental models of human ovarian cancer
Louie, K. G., Hamilton, T. C., Shoemaker, R. H., et al. (1992) · Investigational New Drugs · doi:10.1007/bf00873120 · Cited by 4
CG5/Dx human breast cancer cell line: characterization of a new doxorubicin-resistant variant.
Gibelli, N., Zibera, C., Asti, A., et al. (1996) · PubMed · Cited by 3
Cited by
Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01338-07 · Cited by 427
From genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
Pearse, D. D., Sanchez, A. R., Pereira, F. C., Andrade, C. M., Puzis, R., Pressman, Y., Golden, K., Kitay, B. M., Blits, B., Wood, P. M., et al. (2007) · Glia · doi:10.1002/glia.20490 · Cited by 302
Blais, J. D., Addison, C. L., Edge, R., Falls, T., Zhao, H., Wary, K., Koumenis, C., Harding, H. P., Ron, D., Holcik, M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01145-06 · Cited by 297
Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1542 · Cited by 221
Self-citation
Metadata
- Authors
- Yao, K., Gietema, J. A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N. B., Testa, J., & O'Dwyer, P. J.
- Affiliations
- University of Pennsylvania (US)
- University Medical Center Groningen (NL)
- Fox Chase Cancer Center (US)
- Corresponding author
- O'Dwyer, P J
- Venue
- British Journal of Cancer
- Published
- 2005-12
- Volume
- 93
- Issue
- 12
- Pages
- 1356-1363
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361533
- OpenAlex
- W1970274697
- Cited by
- 82
- References
- 58
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 13 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 4 · 2013: 3 · 2012: 1
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Cancer Institute (R01CA049820, CA-49820)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- hypoxia, colon cancer, HCT116 cells, HT-29 cells, apoptosis, HIF-1, angiogenesis, xenograft tumor growth, cisplatin resistance, DNA damage response, cell proliferation, anti-angiogenic therapy
- MeSH terms
- Adaptation, Physiological, Animals, Cell Survival, Colonic Neoplasms, DNA Damage, Female, Humans, Immunohistochemistry, Neovascularization, Pathologic, Transplantation, Heterologous, Tumor Cells, Cultured, Cell Hypoxia, Mice, SCID, Apoptosis, Drug Resistance, Neoplasm, In Situ Nick-End Labeling, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.